OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$10.62 USD
-0.08 (-0.75%)
Updated May 3, 2024 04:00 PM ET
After-Market: $10.63 +0.01 (0.09%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OPRX 10.62 -0.08(-0.75%)
Will OPRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OPRX
Open Text (OTEX) Q3 Earnings Meet Estimates
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
OPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
New Strong Buy Stocks for January 11th
Other News for OPRX
Wall Street Analysts Are Bullish on Top Healthcare Picks
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), MiMedx Group (MDXG) and Petmed Express (PETS)
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)
Applied Dna Sciences, OptimizeRx, SCWorx among healthcare movers
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET